The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen‐deprivation therapy
暂无分享,去创建一个
M. Papotti | L. Dogliotti | G. Ciccone | E. Bollito | F. Porpiglia | R. Scarpa | M. Volante | A. Berruti | C. Cracco
[1] A. Partin,et al. Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis , 2008, The Prostate.
[2] Francesco Porpiglia,et al. Human ASH1 expression in prostate cancer with neuroendocrine differentiation , 2008, Modern Pathology.
[3] R. Autorino,et al. Neuroendocrine Immunophenotype as Predictor of Clinical Recurrence in 110 Patients with Prostate Cancer , 2007, International journal of immunopathology and pharmacology.
[4] A. Scorilas,et al. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. , 2007, Anticancer research.
[5] M. Papotti,et al. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. , 2007, The Journal of urology.
[6] Toscano Vincenzo,et al. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. , 2007, Endocrine-related cancer.
[7] G. Gatta,et al. Regional Estimates of Prostate Cancer Burden in Italy , 2007, Tumori.
[8] H. Frierson,et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. , 2007, Cancer research.
[9] S. Gunia,et al. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy , 2007, Scandinavian journal of urology and nephrology.
[10] Jiaoti Huang,et al. Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer* , 2006, Journal of Biological Chemistry.
[11] S. Batra,et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. , 2006, Endocrine-related cancer.
[12] M. Cooperberg,et al. The changing face of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Kantoff,et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. , 2005, Urology.
[14] C. Supuran,et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. , 2005, European urology.
[15] L. Dogliotti,et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.
[16] P. Abrahamsson,et al. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.
[17] B. Conley,et al. Detection of Prostate Cancer and Predicting Progression , 2004, Clinical Cancer Research.
[18] S. Monti,et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma , 2003, The Prostate.
[19] P. Scardino,et al. National Comprehensive Cancer Network guidelines for the management of prostate cancer. , 2003, Urology.
[20] D. Bostwick,et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. , 2002, The Journal of urology.
[21] T. H. van der Kwast,et al. Different profiles of neuroendocrine cell differentiation evolve in the PC‐310 human prostate cancer model during long‐term androgen deprivation , 2002, The Prostate.
[22] J. Hugosson,et al. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. , 2000, Urology.
[23] M W Kattan,et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[25] P. di Sant'Agnese,et al. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma , 1998, The Prostate. Supplement.
[26] H. Frierson,et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.
[27] L. McWilliam,et al. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. , 1997, British journal of urology.
[28] A. Partin,et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.
[29] H. Moch,et al. Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.
[30] T. H. van der Kwast,et al. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.